Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation

Figure 4 Enrichment analysis of T cell differentially expressed genes in metabolic dysfunction-associated fatty liver disease hepatocarcinogenesis. A: Differentially expressed genes (DEGs) in IL-CD4+ T cells. Left, metabolic dysfunction-associated fatty liver (MAFL) vs normal control (NC); Right, hepatocellular carcinoma (HCC) vs metabolic dysfunction-associated steatohepatitis (MASH); B: DEGs in IL-CD8+ T cells. Left, MAFL vs NC; Right, HCC vs MASH; C: Top 10 DEGs in IL-CD4+ T cells. Left, MAFL vs NC; Right, HCC vs MASHc; D: Top 10 DEGs in IL-CD8+ T cells. Left, MAFL vs NC; Right, HCC vs MASH; E: Gene Ontology (GO) analysis of DEGs; F: KEGG pathway with distribution of the corresponding GO terms of the top 332 features in hepatocarcinogenesis. ^aP < 0.05, compared with the NC group; NC: Normal control.